Skip to main content

Nausea and Vomiting

2
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
CesametPhase 41 trial
Active Trials
NCT00418678Terminated16Est. Dec 2007
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
AprepitantPhase 2
GSK
GSKLONDON, United Kingdom
1 program
AprepitantPHASE_21 trial
Active Trials
NCT00169572Completed492
Heron Therapeutics
1 program
APF530PHASE_31 trial
Active Trials
NCT00343460Completed1,428Est. Feb 2009
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
1 program
TradipitantPHASE_31 trial
Active Trials
NCT07446439Recruiting280Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthCesamet
Vanda PharmaceuticalsTradipitant
Heron TherapeuticsAPF530
GSKAprepitant

Clinical Trials (4)

Total enrollment: 2,216 patients across 4 trials

A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting

Start: Aug 2006Est. completion: Dec 200716 patients
Phase 4Terminated

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Start: Mar 2026Est. completion: Dec 2026280 patients
Phase 3Recruiting

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Start: Jun 2006Est. completion: Feb 20091,428 patients
Phase 3Completed
NCT00169572GSKAprepitant

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

Start: Feb 2005492 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 2,216 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.